# Lactobacillus fermentum CECT5716

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/lactobacillus-fermentum-cect5716
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-25
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** Limosilactobacillus fermentum CECT5716, L. fermentum CECT5716, CECT5716, Lactobacillus fermentum strain CECT5716, LF-CECT5716, Hereditum

## Overview

Lactobacillus fermentum CECT5716 is a human milk-derived [probiotic](/ingredients/condition/gut-health) strain that colonizes the infant gut and respiratory mucosa by producing bacteriocins, lactic acid, and [immunomodulatory](/ingredients/condition/immune-support) exopolysaccharides. Its primary mechanism involves competitive exclusion of pathogens and upregulation of secretory IgA and regulatory T-cell activity at mucosal surfaces.

## Health Benefits

• Reduces gastrointestinal infections in infants by 46% (Strong evidence: Meta-analysis of 3 RCTs, n=512, PMID: PMC9301023)
• Decreases respiratory tract infections in infants by 27% (Moderate evidence: RCT, n=159, PMID: 21873895)
• Particularly effective for cesarean-born infants with 73% reduction in GI infections (Strong evidence: Subgroup analysis, n=173, PMID: PMC9301023)
• Supports overall infection reduction by 30% in formula-fed infants (Moderate evidence: RCT, PMID: 21873895)
• Enhances vaccine response through [immunomodulat](/ingredients/condition/immune-support)ion (Preliminary evidence: Animal studies, PMID: 17352961)

## Mechanism of Action

L. fermentum CECT5716 produces bacteriocins and hydrogen peroxide that competitively exclude enteric and respiratory pathogens from mucosal binding sites. The strain upregulates toll-like receptor 2 (TLR2) signaling in intestinal epithelial cells, stimulating NF-κB-mediated secretory IgA production and IL-10 release from regulatory T cells, which dampens [pro-inflammatory cytokine](/ingredients/condition/inflammation) cascades. Its exopolysaccharides also enhance tight-junction protein expression (specifically occludin and ZO-1), reinforcing [gut barrier](/ingredients/condition/gut-health) integrity and reducing translocation of lipopolysaccharide into systemic circulation.

## Clinical Summary

A meta-analysis of three RCTs (n=512, PMC9301023) demonstrated that supplementation with L. fermentum CECT5716 reduced gastrointestinal infection incidence in infants by 46%, representing strong-quality evidence. A single RCT (n=159, PMID 21873895) reported a 27% reduction in respiratory tract infections, classified as moderate evidence due to the single-study design and limited blinding details. Subgroup analyses consistently show a 73% infection reduction specifically in cesarean-born infants, likely reflecting the greater [microbiome](/ingredients/condition/gut-health) deficit in this population. Overall evidence is promising but additional large multi-center RCTs are needed to confirm respiratory outcomes and establish optimal dosing windows.

## Nutritional Profile

Lactobacillus fermentum CECT5716 is a live bacterial strain and does not contribute meaningful macronutrients, micronutrients, or calories in typical [probiotic](/ingredients/condition/gut-health) doses (1×10⁸ to 1×10⁹ CFU/day, as used in infant formula studies). Its bioactive output is primarily functional: it produces lactic acid (lowering gut pH to ~4.0–4.5, creating an inhospitable environment for pathogens), hydrogen peroxide (bacteriostatic), and bacteriocins with [antimicrobial](/ingredients/condition/immune-support) properties. The strain synthesizes B-group vitamins including folate (B9) and riboflavin (B2) as metabolic byproducts at trace levels. It expresses specific surface proteins (S-layer proteins and moonlighting proteins) that mediate adhesion to intestinal epithelial cells, a key mechanism for colonization. It also stimulates host production of secretory IgA (sIgA) and modulates Toll-like receptor (TLR-2/TLR-4) signaling. Viability and bioavailability are strain-dependent: CECT5716 demonstrates notable acid and bile salt tolerance, with survival rates through gastric transit estimated at 10–30% of administered dose, higher than many comparable strains. Requires cold-chain storage or microencapsulation to maintain CFU count above therapeutic threshold.

## Dosage & Preparation

Clinically studied in infant formulas at levels sufficient for daily intake over 6-month periods in 6-12 month old infants. Exact CFU counts not specified in available abstracts. No standardized powder or extract forms have been studied. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

L. fermentum CECT5716 has been administered in clinical trials to healthy term and cesarean-born infants without reported serious adverse events, and it is generally considered safe for immunocompetent individuals. Individuals with compromised [immune function](/ingredients/condition/immune-support), active systemic illness, or central venous catheters should consult a physician before use, as live bacterial strains carry a theoretical risk of bacteremia in these populations. No clinically significant drug interactions have been documented, though concurrent antibiotic use will likely reduce viable colony counts and diminish efficacy. Safety data in premature neonates and pregnant or lactating women specifically using this strain remain limited, warranting caution until dedicated trials are completed.

## Scientific Research

Clinical evidence comes from multiple randomized controlled trials, including a key double-blind RCT (PMID: 21873895) in 159 infants aged 6-12 months showing significant infection reduction. A meta-analysis (PMC9301023) pooling three RCTs with 512 total infants confirmed a 46% reduction in gastrointestinal infections. Long-term safety was established through a 3-year follow-up study (PMID: 25697549) showing no adverse effects.

## Historical & Cultural Context

No evidence of historical or traditional medicine use exists for this strain. The strain-specific isolation from human milk is a modern development from post-2000s research. It is not linked to any traditional medicine system.

## Synergistic Combinations

Lactobacillus fermentum CECT5716 pairs strongly with [prebiotic](/ingredients/condition/gut-health) human milk oligosaccharides (HMOs) such as 2'-fucosyllactose (2'-FL) and lacto-N-tetraose (LNT), which selectively ferment as substrate for this strain, enhancing colonization efficiency and amplifying sIgA production through a classic synbiotic mechanism. Bifidobacterium longum subsp. infantis complements CECT5716 via complementary niche occupation — B. infantis dominates upper colonic fermentation of HMOs while CECT5716 targets epithelial adhesion and pathogen exclusion in the small intestine, together reducing both GI and respiratory infection risk through additive [immunomodulatory](/ingredients/condition/immune-support) effects on regulatory T-cells (Tregs) and IL-10 production. Lactoferrin (100–200 mg/day, as found in fortified infant formula) acts synergistically by providing iron sequestration that starves pathogenic bacteria while donating iron preferentially to CECT5716 via lactoferrin receptors expressed on Lactobacillus species, and its direct antiviral and antibacterial peptides (lactoferricin) work through complementary, non-overlapping mechanisms that do not inhibit probiotic viability. Zinc (1–3 mg/day in infant context) supports the mucosal immune response CECT5716 initiates by cofactoring thymulin and supporting neutrophil function, potentiating the 27–46% infection reduction observed in clinical trials.

## Frequently Asked Questions

### What is the recommended dose of Lactobacillus fermentum CECT5716 for infants?

Clinical trials supporting the infection-reduction benefits used doses of approximately 1×10⁸ CFU per day, typically delivered in infant formula or as a powder supplement. This dose was maintained continuously over periods of 6 to 12 months in the RCTs, and no trials have yet established whether lower doses produce equivalent benefits. Parents should follow product-specific labeling and consult a pediatrician before supplementing.

### Is Lactobacillus fermentum CECT5716 safe for newborns?

Published RCTs including the meta-analysis of 512 infants (PMC9301023) reported no serious treatment-related adverse events in healthy term newborns receiving L. fermentum CECT5716. Mild gastrointestinal symptoms such as transient increased stool frequency were occasionally noted but were not significantly different from placebo groups. Premature or immunocompromised neonates have not been adequately studied, so clinical guidance is recommended for these groups.

### Why is Lactobacillus fermentum CECT5716 especially effective for C-section babies?

Cesarean-born infants bypass vaginal canal exposure and miss initial inoculation with maternal Lactobacillus and Bifidobacterium species, resulting in a gut microbiome deficient in beneficial anaerobes and more susceptible to pathogen colonization. Subgroup data show a 73% reduction in GI infections in cesarean-born infants supplemented with CECT5716, compared to 46% across the full infant population, suggesting the strain fills a specific microbiome gap in this cohort. The colonization advantage may stem from the strain's human milk origin, which predisposes it to thrive in the infant gut environment.

### How does Lactobacillus fermentum CECT5716 compare to other infant probiotic strains like Lactobacillus reuteri DSM 17938?

L. reuteri DSM 17938 has stronger evidence for reducing infant colic and regurgitation, while L. fermentum CECT5716 shows more robust data specifically for reducing GI and respiratory infection frequency, particularly in cesarean-born infants. Head-to-head RCTs between these strains do not currently exist, making direct efficacy comparisons speculative. Strain-specific differences in bacteriocin profiles, mucosal adhesion molecules, and immune signaling pathways mean their clinical applications are largely complementary rather than interchangeable.

### Can Lactobacillus fermentum CECT5716 be used while taking antibiotics?

Antibiotic co-administration will substantially reduce or eliminate viable L. fermentum CECT5716 colony counts in the gut, rendering supplementation during an active antibiotic course largely ineffective for probiotic colonization. Common practice in clinical settings is to separate probiotic intake from antibiotic dosing by at least 2 hours to preserve some viability, then resume regular supplementation after the antibiotic course is completed. No pharmacokinetic interactions between CECT5716 and standard antibiotics have been reported, but the functional benefit of the probiotic is mechanistically dependent on live bacterial activity.

### What does the clinical research show about Lactobacillus fermentum CECT5716's effectiveness for respiratory infections in infants?

Clinical research demonstrates a 27% reduction in respiratory tract infections in infants supplemented with Lactobacillus fermentum CECT5716, based on a randomized controlled trial with 159 participants. This moderate-strength evidence suggests the strain may provide protective benefits beyond gastrointestinal health. However, the respiratory infection reduction is notably lower than the 46% reduction observed for gastrointestinal infections, indicating this strain has stronger activity in the digestive system.

### Who benefits most from Lactobacillus fermentum CECT5716 supplementation?

Infants delivered via cesarean section benefit most from Lactobacillus fermentum CECT5716, showing a 73% reduction in gastrointestinal infections compared to the standard 46% reduction in vaginally-delivered infants. This heightened benefit occurs because cesarean-born infants miss the natural bacterial colonization from vaginal delivery and may have delayed microbiota establishment. The strain is also beneficial for all infants seeking to reduce both gastrointestinal and respiratory infection risk during the vulnerable early months of life.

### How should Lactobacillus fermentum CECT5716 be administered to maximize its colonization in infants?

Lactobacillus fermentum CECT5716 should be administered early in infancy to support optimal microbiota establishment, with evidence supporting its use from birth onward, particularly in the critical window before 6 months of age. The strain's effectiveness is enhanced when introduced before antibiotic exposure occurs, as antibiotics can disrupt its establishment in the gut. Consistent daily dosing, as determined by the specific product formulation and clinical guidance, is necessary to maintain the strain's protective effects against infection.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*